Tadalafil

—

evidence score

hormonal

Prescription Only

CialisAdcircatadalafil daily+1 more

Tadalafil is a PDE5 (phosphodiesterase type 5) inhibitor FDA-approved for erectile dysfunction, benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension. Its 36-hour half-life distinguishes it from sildenafil (Viagra, 4-5h) — allowing the "weekend pill" or daily low-dose (5mg) dosing strategies. Beyond sexual function, daily tadalafil has growing evidence for: improved exercise tolerance, reduced blood pressure, anti-inflammatory effects via cGMP pathway, potential neuroprotection, and cardiovascular benefits. At 5mg/day it is FDA-approved for both ED and BPH, and is widely used off-label as part of longevity and cardiovascular optimization protocols.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Dosing

Typical

5 mg

2.5 mgRange20 mg

Frequencydaily (5mg) or as needed (10-20mg)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~17.5 hours

OnsetErectile effects within 1 hour; daily dosing steady-state in 5 days

DurationUp to 36 hours per dose; daily dosing maintains continuous effect

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Tadalafil is currently categorized as a hormonal compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Selective PDE5 inhibitor; prevents cGMP degradation in vascular smooth muscle → eNOS-derived NO maintains vasodilation → sustained vasodilation in penile corpus cavernosum, pulmonary vasculature, prostate

Practical Context

Strongest current signals

No indexed study summaries yet.

Elevated caution signals

1 severe/high side effect flag